Prescription drug · ANDA
Acarbose NDC 71335-9725
Acarbose 50 mg/1 · Tablet · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71335-9725-1 | 71335972501 | 30 TABLET in 1 BOTTLE (71335-9725-1)Marketed from Sep 11, 2023 | |
| 71335-9725-2 | 71335972502 | 90 TABLET in 1 BOTTLE (71335-9725-2)Marketed from Aug 12, 2024 | |
| 71335-9725-3 | 71335972503 | 100 TABLET in 1 BOTTLE (71335-9725-3)Marketed from Aug 12, 2024 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Acarbose
- Generic name (nonproprietary)
- acarbose
- Active ingredients
- Acarbose — 50 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202271
- Marketing start
- Listing expires
- Other FDA classes
- alpha Glucosidase Inhibitors (Mechanism)
- Identifiers
- Product ID 71335-9725_748a173e-196a-4509-8736-352a31a28434SPL ID 748a173e-196a-4509-8736-352a31a28434SPL set ID 067c0adc-7322-489d-9baa-1d061b37be36RxCUI 199149UNII T58MSI464G
- Pharmacologic class
- alpha-Glucosidase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471335972501followed by a unit qualifier and the quantityPackage 71335-9725-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Acarbose tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 202271
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Acarbose | Acarbose 100 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-149 |
| Acarbose | Acarbose 25 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-147 |
| Acarbose | Acarbose 50 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-148 |
| Acarbose | Acarbose 25 mg/1 | TabletOral | Chartwell RX, LLC | 62135-453 |
| Acarbose | Acarbose 50 mg/1 | TabletOral | Chartwell RX, LLC | 62135-454 |
| Acarbose | Acarbose 100 mg/1 | TabletOral | Chartwell RX, LLC | 62135-455 |